Purple Reishi

Metadata

Regulatory Status

Chinese Pharmacopoeia

• Listed: Yes. Ganoderma sinense is one of only two official Ganoderma species in the Chinese Pharmacopoeia (2020 edition), alongside G. lucidum. Both are recognized under the drug name Lingzhi (灵芝).
• Dual-use status: Ganoderma (including both G. lucidum and G. sinense) holds official dual status as both food and traditional Chinese medicine in China.
• GSP tablet approval: In 2010, Ganoderma sinense polysaccharide (GSP) tablets were approved by China’s State Food and Drug Administration (SFDA) as an adjunctive therapeutic drug for treating leukopenia and hematopoietic injury caused by concurrent chemotherapy and radiation therapy during cancer treatment.
• Traditional indications: Tonifying qi, calming the spirit, relieving cough and dyspnea. Used for dizziness, insomnia, palpitations, and deficiency-pattern shortness of breath.
• Official dose: 6—12 g in decoction (as dried fruiting body).

Classical Chinese Texts

• G. sinense corresponds to “Zizhi” (Purple Mushroom) in the ancient six-color classification of Lingzhi, first described in the Shennong Bencao Jing (circa 200 CE) and later codified by Li Shizhen in the Bencao Gangmu (1596).
• The six classical Lingzhi are: Qingzhi (Green, liver), Chizhi (Red, heart), Huangzhi (Yellow, spleen), Baizhi (White, lung), Heizhi (Black, kidney), and Zizhi (Purple, essence/vitality).
• Zizhi was traditionally associated with nourishing essence (jing) and benefiting the joints, and was considered one of the most valued of the six types.

United States

• Dietary supplement: Not widely marketed as a standalone species in the US supplement market. Most “Reishi” products sold in the US are derived from G. lucidum or unspecified Ganoderma species.
• FDA GRAS status: No specific GRAS determination.

European Union

• Novel food: No specific authorization for G. sinense extracts. The EU Novel Food Catalogue does not differentiate between Ganoderma species at a granular level, but concentrated extracts would likely require novel food authorization.
• EMA/HMPC: No monograph exists.

Japan and Korea

• Japan: Not listed in the Japanese Pharmacopoeia. Available as a health food ingredient.
• Korea: Recognized in Korean traditional medicine (Hanbang). Less commonly cultivated than G. lucidum.

Conditions & Indications

Primary: Immune Support and Adjunctive Cancer Therapy (Preliminary Evidence)

• Chemo/radiation-induced leukopenia: The GSP tablet is approved in China as an adjunctive drug for treating leukopenia and hematopoietic injury caused by concurrent chemo/radiation therapy. Preclinical studies demonstrate that GSP stimulates bone marrow hematopoiesis and promotes white blood cell recovery. However, the clinical trial data supporting this approval have not been published in accessible peer-reviewed databases, limiting independent evaluation of the evidence.
• Immunomodulation: G. sinense polysaccharides activate innate immune cells through TLR4 signaling, stimulating macrophage production of nitric oxide, TNF-alpha, and IL-1beta. The polysaccharide GSP-2 has been identified as a specific TLR4 agonist, providing a defined molecular mechanism for immune activation.

Secondary: Antioxidant and Hepatoprotective Effects (Preclinical Evidence)

• Antioxidant activity: G. sinense extracts demonstrate free radical scavenging activity in vitro, attributed to both polysaccharide and triterpenoid fractions. Preclinical models suggest potential for reducing oxidative stress markers.
• Hepatoprotection: Animal studies suggest protective effects against chemically induced liver injury, consistent with traditional TCM use for liver support and the classical association of certain Lingzhi types with organ protection.

Emerging: Antitumor and Mushroom-Poison Detoxification (Preclinical)

• Direct antitumor activity: Polysaccharides from G. sinense demonstrated tumor-suppressive activity in sarcoma-bearing mice, comparable to that of G. lucidum polysaccharides. The mechanism appears to be primarily immunomodulatory rather than directly cytotoxic.
• Mushroom-poison detoxification: Unique among Ganoderma species, GSP has been reported to possess mushroom-poison detoxification properties in preclinical models, though this application requires further investigation.

Mechanism of Action

Primary Mechanisms

1. TLR4-mediated immune activation: GSP-2, a polysaccharide extracted from G. sinense fruiting bodies, functions as a toll-like receptor 4 (TLR4) agonist, activating NF-kB signaling in macrophages and stimulating production of pro-inflammatory mediators (NO, TNF-alpha, IL-1beta, IL-6). This mechanism provides the pharmacological basis for immune enhancement and the approved indication for leukopenia recovery.

2. Beta-glucan innate immune stimulation: Like other medicinal Ganoderma species, G. sinense contains beta-(1,3)-D-glucans with (1,6) branching that activate innate immune cells through dectin-1 and TLR-2 receptors, promoting macrophage phagocytosis, NK cell cytotoxicity, and dendritic cell maturation.

3. Hematopoietic stimulation: Preclinical evidence suggests that GSP promotes bone marrow hematopoiesis, supporting recovery of white blood cell counts following chemo/radiation-induced myelosuppression. The precise molecular mechanism remains under investigation.

Secondary Mechanisms

• Triterpenoid-mediated activities: G. sinense contains lanostane triterpenoids including ganoderic acids Jc and Jd, though in substantially lower quantities and with a different profile than G. lucidum. These triterpenoids exhibit anti-inflammatory and cytotoxic activity in vitro, but the clinical relevance of the triterpenoid fraction in G. sinense is less established than for G. lucidum.
• CYP450 inhibition: Ganoderma triterpenoids broadly inhibit cytochrome P450 enzymes, particularly CYP1A2, though G. sinense has a weaker triterpenoid profile than G. lucidum. The clinical significance of CYP inhibition by G. sinense specifically has not been established.
• Antioxidant activity: Both polysaccharide and triterpenoid fractions scavenge free radicals and upregulate endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase) in preclinical models.

Critical Species Distinction

Despite both being listed in the Chinese Pharmacopoeia under the same drug name (Lingzhi), G. sinense and G. lucidum have significantly different triterpenoid profiles. G. lucidum is rich in ganoderic acids with established anti-inflammatory, anti-tumor, and hepatoprotective activities; G. sinense contains relatively few ganoderic acids in small amounts. Conversely, their polysaccharide fractions share comparable structural features (mono-/oligosaccharide profiles, molecular size, sugar linkages) and exhibit similar tumor-suppressive activity in preclinical models. This divergence means the two species should not be considered pharmacologically interchangeable, particularly for triterpenoid-driven indications.

Clinical Evidence Summary

Clinical evidence specifically for G. sinense is extremely limited in the peer-reviewed English-language literature. The GSP tablet has regulatory approval in China, but the supporting clinical trial data have not been published in accessible databases.

GSP Tablet for Chemo/Radiation-Induced Leukopenia

Preclinical Evidence (Selected)

Evidence Limitations

• The most significant clinical evidence — the GSP tablet approval data — is not available in accessible peer-reviewed databases, preventing independent evaluation of study design, sample size, endpoints, and statistical rigor.
• Most pharmacological evidence derives from in vitro and animal studies.
• The majority of published research on Ganoderma medicinal properties focuses on G. lucidum, and extrapolation to G. sinense is only partially valid due to the triterpenoid profile differences.
• No independently published RCTs in English-language literature specifically evaluate G. sinense for any clinical indication.
• The dual listing with G. lucidum in the Chinese Pharmacopoeia may lead to conflation of evidence between the two species in clinical practice and commercial products.

Safety Profile

General Assessment

G. sinense has a long history of traditional use in China spanning over 2,000 years. The GSP tablet has regulatory approval in China, implying safety evaluation during the drug approval process, though these data are not publicly accessible. The safety profile is generally extrapolated from the broader Ganoderma genus, particularly G. lucidum, for which more extensive safety data exist.

Contraindications

• Pregnancy and lactation: Contraindicated due to insufficient safety data. No human studies in pregnant women.
• Autoimmune disease: Theoretical concern that immunostimulatory beta-glucan polysaccharides and TLR4 activation could exacerbate autoimmune conditions. Clinical evidence for this interaction is lacking, but the theoretical concern is plausible given the demonstrated immune-activating mechanism.
• Pre-surgical: Discontinue at least 2 weeks before surgery due to potential antiplatelet activity (extrapolated from Ganoderma genus data).

Drug Interactions

• Immunosuppressants (cyclosporine, tacrolimus, cyclophosphamide): GSP’s TLR4-mediated immune activation may counteract immunosuppressive therapy. Avoid concurrent use in transplant patients without physician supervision. This interaction is particularly relevant given the approved oncology indication.
• Anticoagulants and antiplatelets: Theoretical increased bleeding risk based on Ganoderma genus antiplatelet activity data. Clinical evidence specific to G. sinense is lacking.
• Chemotherapy agents: The GSP tablet is specifically approved for concurrent use with chemotherapy and radiation in China, suggesting acceptable safety in this context based on the (unpublished) approval data. However, independent verification is not possible.
• CYP450 substrates: Ganoderma triterpenoids inhibit CYP1A2 and potentially other CYP enzymes. G. sinense has a weaker triterpenoid profile than G. lucidum, so this interaction may be less clinically relevant.

Side Effects

• Common: Gastrointestinal discomfort (nausea, loose stools) reported with Ganoderma preparations generally.
• Uncommon: Allergic reactions in individuals with fungal sensitivities.
• Rare: Hepatotoxicity has been reported in rare case reports with Ganoderma preparations, though causality is difficult to establish.

Quality Concerns

• Species authentication is critical, as G. sinense and G. lucidum are sometimes conflated commercially. Morphological identification can be unreliable; DNA barcoding is recommended for definitive species confirmation.
• The dark-colored, often unlacquered pileus of G. sinense distinguishes it from the typically reddish-brown, lacquered G. lucidum, but intermediate forms and other Ganoderma species can complicate identification.

Clinical Dosage

Traditional Decoction (Chinese Pharmacopoeia)

• Standard dose: 6—12 g/day of dried fruiting body in decoction
• This is the official dosage listed in the Chinese Pharmacopoeia for Lingzhi (encompassing both G. sinense and G. lucidum)

GSP Tablet (Approved Drug in China)

• Dose: Per manufacturer labeling (specific dosage information not available in accessible literature)
• Indication: Adjunctive treatment for leukopenia and hematopoietic injury during concurrent chemotherapy and radiation therapy
• Note: This is a regulated pharmaceutical product in China, not a dietary supplement

Dried Fruiting Body Powder

• Estimated dose: 3—6 g/day of dried fruiting body powder, extrapolated from Ganoderma genus dosing conventions
• Note: No specific clinical trial dosing data available for G. sinense fruiting body preparations outside the GSP tablet

Hot-Water Extract

• Estimated dose: Equivalent to 3—6 g dried fruiting body per day
• Extraction: Hot-water extraction captures the polysaccharide fraction, which is the primary bioactive component with the most evidence
• Note: Dual extraction (hot water + ethanol) would also capture triterpenoids, though the triterpenoid fraction of G. sinense is less pharmacologically characterized than that of G. lucidum

Form Selection Guidance

The polysaccharide fraction is the primary evidence-based bioactive component of G. sinense, supported by the GSP tablet approval and preclinical immunomodulatory data. Hot-water extraction is appropriate for polysaccharide capture. Given the weaker triterpenoid profile relative to G. lucidum, dual extraction may offer less incremental benefit for G. sinense than for G. lucidum. For triterpenoid-driven indications (anti-inflammatory, direct cytotoxic), G. lucidum may be a more appropriate species selection.

Sources

• Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Vol 1. 2020 Edition
• Li J, Gu F, Cai C, Hu M, Fan L, Hao J, Yu G. Comprehensive comparison of polysaccharides from Ganoderma lucidum and G. sinense: chemical, antitumor, immunomodulating and gut-microbiota modulatory properties. Sci Rep. 2018;8(1):6172
• Zhao YY, Shen X, Chao X, Ho CC, Cheng XL, Zhang Y, et al. GSP-2, a polysaccharide extracted from Ganoderma sinense, is a novel toll-like receptor 4 agonist. PLoS One. 2019;14(8):e0221027
• Chen Y, Bicker W, Wu J, Xie MY, Lindner W. Comparison of two officinal Chinese pharmacopoeia species of Ganoderma based on chemical research with multiple technologies and chemometrics analysis. J Chromatogr A. 2012;1222:59-68
• Li LF, Liu HB, Zhang QW, Li ZP, Wong TL, Fung HY, et al. Overview of Ganoderma sinense polysaccharide — an adjunctive drug used during concurrent chemo/radiation therapy for cancer treatment in China. Biomed Pharmacother. 2018;96:865-870
• Xu JW, Zhao W, Zhong JJ. Ganoderma sinense polysaccharide: an adjunctive drug used for cancer treatment. Prog Mol Biol Transl Sci. 2019;163:165-177
• Baby S, Johnson AJ, Govindan B. Secondary metabolites from Ganoderma. Phytochemistry. 2015;114:66-101
• Wang XC, Xi RJ, Li Y, Wang DM, Yao YJ. The species identity of the widely cultivated Ganoderma, ‘G. lucidum’ (Ling-zhi), in China. PLoS One. 2012;7(7):e40857
• Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev. 2007;13:265-301
• Li Shizhen. Bencao Gangmu (Compendium of Materia Medica). 1596. Zhi category
• Wu SH, Ryvarden L, Chang TT. Ganoderma australe — a new record for Taiwan. Mycotaxon. 1997;64:173-179

Connections

• Ganoderma lucidum (Red Reishi): Reishi is the closely related and more widely studied species. Both are listed in the Chinese Pharmacopoeia under the same drug name (Lingzhi), but they have significantly different triterpenoid profiles. G. lucidum is richer in ganoderic acids, while G. sinense polysaccharides are structurally comparable. For triterpenoid-driven indications, G. lucidum is the better-characterized choice; for polysaccharide-driven immune modulation, both species appear comparable.
• Ganoderma applanatum (Artist’s Conk): Ganoderma applanatum is another Ganoderma species with traditional medicinal use and polysaccharide-driven bioactivity, representing the broader genus diversity.
• Turkey Tail (Trametes versicolor): Turkey Tail shares the polysaccharide-driven immune activation mechanism and has the most developed clinical evidence among medicinal mushrooms for cancer adjunctive therapy (PSK/Krestin in Japan). The GSP tablet for G. sinense represents a parallel approach in China.
• Maitake (Grifola frondosa): Maitake beta-glucans (particularly the D-fraction) share similar dectin-1/TLR-mediated immune activation pathways, making it a complementary species for immune support protocols.
• Six classical Lingzhi context: G. sinense (Zizhi, Purple Mushroom) is traditionally associated with nourishing essence and vitality. This ancient six-color classification system — predating modern taxonomy by over 1,500 years — demonstrates the deep historical roots of Ganoderma medicinal use in Chinese culture, though the exact species identities of all six classical types remain debated by modern mycologists.